Virosome studied by MedImmune

By Dylan Bushell-Embling
Friday, 18 July, 2008

Technology developed by Norwood Abbey's [ASX: NAL] second-tier subsidiary Virosome Biologicals is being evaluated by US company MedImmune.

The companies have signed a six-month exclusive evaluation agreement over Virosome's virosomal vaccine technology. In this time the companies will collaborate on research using the virosome technology with MedImmune vaccine candidates.

MedImmune is a member of the AstraZeneca group.

Genetics shape our personality and life outcomes more than we thought

Scientists have identified more than 1200 genetic variants associated with personality traits,...

High folic acid in pregnancy could cause early bleeding

Women taking at least 800 micrograms of folic acid daily were more likely to report spotting and...

Scientists uncover how cancer cells hide from immune system

By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...

Content from other channels on our network

Barry Callebaut's low-carbon dairy partnership with Arla Foods

Product profile: making multihead weighing easier for operators

Advances in the kokumi 'taste sensation' for food

Six on the shelf: functional drink, protein-powered snack and more

Dr Mark Krstic is stepping down as MD of AWRI

Remote telemetry for Tasmanian irrigation

Critical industries need to know how to isolate, rather than ignore

Guide to assessing low‍-‍emissions thermal energy storage released

WA invests in local wind generator repair and refurbishment

UTS pilot project to mitigate methane emissions

SEW projects to deliver six billion litres of recycled water annually

UNSW expert awarded Eureka Prize for sustainability

$26 million to fund Australian-made iron technology

Beyond compliance: why ESG in construction is becoming a people issue

Environmental site restoration to transform sewage treatment plant